A Clinical Study of AFN50 in the Treatment of Autoimmune Diseases

StatusWithdrawn
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status changed: Recruiting → Withdrawn Sponsor's reason: No participants. Show 5 more changesShow less
    • Enrollment target: estimated 18 to confirmed 0
    • Primary completion date changed from estimate of Feb 29, 2028 to Apr 30, 2026
    • Secondary endpoints: details revised at 2 of 5 entries
    • Site details revised
    • Eligibility criteria shortened, about 5 words
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Mar 1, 2026 to Mar 9, 2026
    v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
This study is a single-arm, open-label, single-centre exploratory clinical trial designed to evaluate the safety, tolerability, and preliminary efficacy of AFN50 Injection in adult patients with B-cell-mediated refractory/replapased autoimmune diseases.
Trial Details
NCT Number NCT07448298
Lead Sponsor Beijing Boren Hospital
Conditions
(from sponsor)		 Relapsed/Refractory Autoimmune Diseases
Related terms Autoimmune Diseases
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov